Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403

Immunochemotherapy followed by autologous transplant (ASCT) in CALGB/Alliance 59909 achieved a median progression-free survival (PFS) in mantle cell lymphoma (MCL) of 5 years, but late recurrences occurred. We evaluated tolerability and efficacy of adding post-transplant bortezomib consolidation (BC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Hematol
Autores principales: Kaplan, Lawrence D., Maurer, Matthew J., Stock, Wendy, Bartlett, Nancy L., Fulton, Noreen, Pettinger, Adam, Byrd, John C., Blum, Kristie A., LaCasce, Ann S., Hsi, Eric D., Liu, Yi Tian, Scott, David W., Hurd, David, Ruppert, Amy S., Hernandez-Ilizaliturri, Francisco, Leonard, John P., Cheson, Bruce. D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486983/
https://ncbi.nlm.nih.gov/pubmed/32170769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25783
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares